Boston Scientific Corporation (BSX) — Insider Activity & Signal

Healthcare · Medical - Devices · Market cap $73.3B · $49.31 · 52-week range $42.20–$109.50

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-08-05	Habiger David C	director	2,100	$47.59	$99,937	SEC Form 4
2026-08-04	Habiger David C	director	140	$48.59	$6,802	SEC Form 4
2026-08-03	Habiger David C	director	1,042	$48.07	$50,084	SEC Form 4
2026-08-03	Mahoney Michael F	director, officer: Chairman, President & CEO	186,240	$48.33	$9,001,408	SEC Form 4
2026-07-31	LUDWIG EDWARD J	director	5,000	$45.48	$227,400	SEC Form 4
2026-05-20	Pegus Cheryl	director	1,770	$56.49	$99,987	SEC Form 4
2026-05-20	LUDWIG EDWARD J	director	3,580	$56.68	$202,914	SEC Form 4
2026-05-20	Habiger David C	director	2,250	$55.92	$125,819	SEC Form 4
2026-05-19	Habiger David C	director	2,200	$56.95	$125,279	SEC Form 4

Financial health

Altman Z-Score 3.26 · Piotroski F-Score 8/9 · Cash $2.0B · Debt $12.4B

ClearOcean signal read

ClearOcean's model currently scores BSX as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — BSX Form 4
How ClearOcean reads insider activity

Last updated August 08, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.